|Year : 2022 | Volume
| Issue : 3 | Page : 281-283
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in a case of subcutaneous T-cell lymphoma presenting as breast mass and panniculitis-like features: A rare entity
Ayush Mishra, Vivek Kumar Saini, Bela Jain, Amitabh Arya, Manish Ora, Sanjay Gambhir
Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
|Date of Submission||13-Sep-2021|
|Date of Acceptance||30-Nov-2021|
|Date of Web Publication||02-Nov-2022|
Dr. Manish Ora
Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow - 226 014, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an unusual subtype of cutaneous lymphoma and clinically appears as erythematous, subcutaneous infiltrates, and recurrent papulonodules. It is deﬁned as a rare cytotoxic a/b T-cell lymphoma characterized by primary involvement of subcutaneous tissue-mimicking panniculitis and a predominant CD3+/CD4/CD8+ phenotype in (2005) the World Health Organization-European Organization for Research and Treatment of Cancer classiﬁcation for cutaneous lymphomas. On metabolic imaging, these lesions are invariably fluorodeoxyglucose (FDG) avid. SPTCL which presents as a breast mass is a rare entity. Here, we present a case of SPTCL presents as FDG avid breast mass and subcutaneous nodules.
Keywords: Breast mass, fluorodeoxyglucose positron emission tomography/computed tomography, subcutaneous panniculitis-like T-cell lymphoma
|How to cite this article:|
Mishra A, Saini VK, Jain B, Arya A, Ora M, Gambhir S. F-18 fluorodeoxyglucose positron emission tomography/computed tomography in a case of subcutaneous T-cell lymphoma presenting as breast mass and panniculitis-like features: A rare entity. Indian J Nucl Med 2022;37:281-3
|How to cite this URL:|
Mishra A, Saini VK, Jain B, Arya A, Ora M, Gambhir S. F-18 fluorodeoxyglucose positron emission tomography/computed tomography in a case of subcutaneous T-cell lymphoma presenting as breast mass and panniculitis-like features: A rare entity. Indian J Nucl Med [serial online] 2022 [cited 2022 Nov 29];37:281-3. Available from: https://www.ijnm.in/text.asp?2022/37/3/281/360257
A 53-year-old female patient with on and off fever and swelling in the right breast for 2 months was referred to our department for fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Ultrasonography of the right breast depicted a lesion in lower medial quadrant. Excisional biopsy on the right breast was showing infiltration and rimming of the adipocyte cells by many atypical lymphoid admixed with few histiocytes and plasma cells. The atypical cells are medium-sized, have high n/c ratio, prominent nucleoli at places, and scant amount of cytoplasm. On immunohistochemistry, these cells are positive for CD 3 and negative for CD 4, CD 8, CD 30, and CD 20. FDG PET/CT of the patient was planned which revealed an ill-defined FDG avid (SUV max-4.6) soft-tissue density lesion in inner quadrant of the right breast with relative sparing of the nipple-areola complex and multiple areas of cutaneous and subcutaneous soft-tissue thickening and also soft-tissue thickening in the right breast parenchyma [Figure 1] and [Figure 2]. The patient underwent three cycles of Cyclophosphamide, Hydroxydaunorubicin, Etoposide: Oncovin, Prednisolone (CHEOP) and underwent PET/CT. PET/CT revealed decrease in the number, size, and avidity of previously seen soft-tissue lesion suggestive of partial metabolic response (Deauville score II). After, this patient underwent three more cycles of chemotherapy (CHEOP). Postchemotherapy PET/CT was suggestive of complete metabolic response (Deauville score). T-cell lymphoma (TCL) is invariably FDG avid, allowing FDG PET/CT to be used for pretreatment staging and restaging.
|Figure 1: (a) Maximum intensity projection image of the whole body of baseline positron emission tomography/computed tomography, revealing multiple fluorodeoxyglucose avid subcutaneous and cutaneous soft-tissue thickening, soft-tissue thickening in the right breast parenchyma with axillary and pelvic lymphadenopathy. (b) Fused coronal positron emission tomography/computed tomography show similar changes. (c and d) Interim and end of treatment positron emission tomography/computed tomography shows partial and complete metabolic response, respectively|
Click here to view
|Figure 2: (a-f) Fused axial images of breast lesion, axillary, and pelvic lymph node in the baseline and end of treatment positron emission tomography/computed tomography, respectively|
Click here to view
Subcutaneous panniculitis-like TCL (SPTCL) is a rare subtype of cutaneous TCL. It was first described by Gonzalez et al. in 1991. The disease was recognized by the World Health Organization and the International Lymphoma Study Group in 1994 as a distinct entity in the recent classification of lymphomas. SPTCL is divided into two major subgroups (αβ-STCL and γδ-STCL), depending on the T-cell receptor expression on the malignant T-cells. γδ-STCL is often associated with a more aggressive course and poor prognosis. It presents as multiple indurated, poorly circumscribed, firm, violaceous cutaneous plaques, and nodules mimicking lobular panniculitis. Sometimes it may lead to aggressive hemophagocytic syndrome infrequently. Involvement of lymph nodes or other visceral organs is rarely reported. omentum may be involved.,,,
The role of PET/CT in SPTCL is still evolving, attributable to the rarity and heterogenicity of disease presentation. Imaging findings may simulate various inflammatory and malignant pathologies., The involvement of breast parenchyma in SPTCL is a rare finding, and only a few case reports are found in the literature., Imaging features addressed in the previous studies of breast lymphoma are generally nonspecific and inadequate to guide clinical practice. It is of the utmost importance SPTCL breast mass does not require surgery like carcinoma. We illustrate a rare case of SPTCL presenting as a breast mass. FDG PET/CT helped in pretherapy staging and response evaluation in this case.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.
Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelényi G, et al.
Updated Kiel classification for lymphomas. Lancet 1988;1:292-3.
Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper DL, Foss F (2008) Outcomes in subcutaneous panniculitis-like T-cell Lymphoma (STCL). Blood 2008: (ASH Annual Meeting Abstracts)112:3750.
Schramm N, Pfluger T, Reiser MF, Berger F. Subcutaneous panniculitis-like T-cell lymphoma with breast involvement: Functional and morphological imaging findings. Br J Radiol 2010;83:e90-4.
Bikkina P, Reddy K, Ali Z, Kumar N. Positron emission tomography-computed tomography in subcutaneous panniculitis-like T-cell lymphoma. World J Nucl Med 2019;18:428-30.
] [Full text]
Uematsu T, Kasami M. 3T-MRI, elastography, digital mammography, and FDG-PET CT findings of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) of the breast. Jpn J Radiol 2012;30:766-71.
Lee HJ, Im JG, Goo JM, Kim KW, Choi BI, Chang KH, et al.
Peripheral T-cell lymphoma: Spectrum of imaging findings with clinical and pathologic features. Radiographics 2003;23:7-26.
Ou X, Wang J, Zhou R, Zhu S, Pang F, Zhou Y, et al.
Ability of 18
F-FDG PET/CT radiomic features to distinguish breast carcinoma from breast lymphoma. Contrast Media Mol Imaging 2019;2019:4507694.
[Figure 1], [Figure 2]